NASDAQ · IXHL
Incannex Healthcare Limited
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
Loading market information…
ASX · PXS.AX · AUD
Stock price, earnings
Quote as of Dec 6, 2023, 11:06 PM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Pharmaxis Ltd’s quoted price sits in the lower half of its reported 52-week range, 56.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pharmaxis Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pharmaxis Ltd, an Australian biopharmaceutical company founded in 1998 and based in Frenchs Forest, is globally focused on discovering, developing, and commercializing healthcare solutions for fibrotic and inflammatory conditions. Its operations are organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. Currently, Pharmaxis markets Bronchitol, an inhaled dry powder used in the treatment of cystic fibrosis, and Aridol, a diagnostic tool that identifies hyper-responsive airways to aid in the diagnosis and management of asthma. The company's robust pipeline features several promising candidates. These include oral pan-lysyl oxidase (LOX) inhibitors targeting myelofibrosis and various other cancers, as well as topical pan-LOX inhibitors designed to address skin scarring caused by injuries, surgical procedures, and burns. Pharmaxis is also advancing selective Lysyl Oxidase Like Inhibitors (LOXL2) for a range of chronic fibrotic diseases, such as those affecting the kidneys, lungs, liver, and heart. Additionally, it is investigating semicarbazide-sensitive amine oxidase for potential use in neuro-inflammatory diseases. Further development includes Orbital, an innovative dry powder inhaler engineered to deliver high drug doses effectively to the lungs.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
A$0.01A$0.00 (0.0%)
Creso Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 83.02% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
A$0.04A$0.00 (0.0%)
CardieX Limited’s quoted price sits in the lower half of its reported 52-week range, 79.43% below the high.
A$0.42+A$0.01 (+2.44%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.18% below the high.
A$0.04A$0.00 (0.0%)
AusCann Group Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 4.76% below the high.
A$0.01+A$0.00 (+22.22%)
1st Group Limited’s quoted price sits in the upper half of its reported 52-week range, 26.67% below the high.
A$0.04A$0.00 (0.0%)
Asian American Medical Group Limited: Healthcare · Medical - Care Facilities.
